1. Scrip
  2. >>Business

Early API Momentum At Indian Firms: Not Just A Quarterly Bump?

 
• By Anju Ghangurde

Alembic and Biocon kick off the Q1 earnings season in India with significant growth in the active pharmaceutical ingredients business and expect to see continued momentum in the area. More Indian firms could gain as customers realign strategies and move away from single sources to de-risk their supply chain, learning from pandemic-related disruptions.

Business improvement (ImageFlow/Shutterstock.com)
API Sales Of Indian Firms Spurt In Q1 • Source: Shutterstock

The first-quarter fiscal 2021 earnings of India's Alembic Pharmaceuticals Limited and Biocon, Ltd. have reflected strong traction in the active pharmaceutical ingredients (APIs) business against the backdrop of coronavirus pandemic-related disruptions as customers stocked up to ensure business continuity.

While APIs are not the biggest contributor to the revenues of both the front-line companies, which have distinct profiles and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By Joseph Haas

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 
• By Alaric DeArment

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

 
• By Jessica Merrill

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.